VUNO's AI-Powered Cardiac Arrest Risk Management System Earns CE MDR and UKCA Certifications
SEOUL, South Korea, May 12, 2025 /PRNewswire/ -- VUNO, a leading South Korean medical AI company, announced today that its flagship AI-powered cardiac arrest risk management system VUNO Med®-DeepCARS®(DeepCARS) has received CE MDR (Medical Device Regulation) certification in the European Union, as well as the UKCA (UK Conformity Assessed) mark in the United Kingdom. Achieving these regulatory milestones more than a year ahead of schedule significantly accelerates the company's global market entry.
The CE MDR certification affirms the clinical safety and effectiveness of VUNO's solution across the 27 EU member states, enabling the company to actively pursue expansion in European markets. VUNO plans to collaborate with experienced local AI healthcare partners who have successfully introduced similar solutions in the region to streamline hospital adoption and reimbursement processes.
Simultaneously, VUNO is preparing to enter the Middle Eastern market, where CE MDR and U.S. FDA certifications are commonly recognized as key references in the regulatory process, supporting a smoother pathway to market entry. With CE MDR in hand, the company aims to complete regulatory registrations in key Middle Eastern countries within the year and initiate full-scale operations across the region by 2026.
"This milestone marks a pivotal step in VUNO's mission to bring AI-driven innovation in critical care to the global stage," said Dr. Ye Ha Lee, Founder & CEO of VUNO. "DeepCARS is already being used in over 130 hospitals across South Korea. With this proven track record, we are confident in its potential to contribute to patient safety in hospitals around the world."
About VUNO Med ® -DeepCARS ®
VUNO Med®-DeepCARS®(DeepCARS) is an AI-powered medical device designed to monitor the risk of in-hospital cardiac arrest within the next 24 hours. It analyzes patients' vital signs-including blood pressure, heart rate, respiratory rate, and body temperature-in general wards.
As of April 2025, DeepCARS has been implemented across more than 48,000 hospital beds in South Korea, including over 20 tertiary general hospitals, establishing itself as an essential part of care. In 2023, DeepCARS received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently undergoing the FDA approval process.
About VUNO
VUNO, founded in 2014, is a leading South Korean medical AI company and the developer of the nation's first approved AI-powered medical device. Leveraging cutting-edge AI technology, VUNO analyzes a wide range of medical data — from bio signals such as ECG, respiratory rate and blood pressure to medical images including X-rays, CT scans, and fundus images — to predict critical events and support clinicians in decision-making.
Committed to patient-centered innovation, VUNO strives to make high-quality healthcare accessible to everyone, worldwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
35 minutes ago
- Korea Herald
Seoul shares nearly flat amid renewed tariff woes
South Korean stocks finished slightly higher Monday, as investors took a wait-and-see posture ahead of the crucial presidential election amid signs of renewed trade tensions between the United States and China. The local currency rose against the US dollar. The benchmark Korea Composite Stock Price Index added 1.3 points, or 0.05 percent, to close at 2,698.97. Trade volume was moderate at 320.32 million shares worth 7.99 trillion won ($5.82 billion), with losers beating winners 523 to 369. Foreign and retail investors bought a net 127.34 billion won and 98.7 billion won worth of stocks, respectively, while institutions sold 240.17 billion won worth of shares. The index opened lower but soon turned higher, rising nearly 1 percent. But it had moved in and out of negative territory before ending slightly higher. Investor sentiment was dampened as US President Donald Trump said last week that he planned to double tariffs on foreign imports of steel to 50 percent. He also upped trade tensions by accusing China of violating a trade agreement with the US ahead of a scheduled call with Chinese President Xi Jinping to address trade issues. On the domestic front, South Korean voters were set to cast their ballots to choose a president Tuesday after former President Yoon Suk Yeol was ousted following the short-lived imposition of martial law. Front-runner Lee Jae-myung of the Democratic Party was vying against Kim Moon-soo of the conservative People Power Party. Top-cap shares finished mixed. Market bellwether Samsung Electronics surged 1.07 percent to 56,800 won, and its rival SK hynix jumped 1.47 percent to 207,500 won. But major battery maker LG Energy Solution fell 0.52 percent to 284,500 won, and leading biotech firm Samsung Biologics edged down 0.1 percent to 1.03 million won. Steelmakers lost ground. No. 1 steelmaker POSCO Holdings sank 2.4 percent to 244,000 won, and Hyundai Steel tumbled 2.66 percent to 27,450 won. Carmakers also fell. Top carmaker Hyundai Motor dipped 0.7 percent to 184,000 won, and its sister Kia Motors went down 1.12 percent to 88,400 won. Defense giant Hanwha Aerospace advanced 2.96 percent to 835,000 won, while leading financial firm KB Financial retreated 4.12 percent to 100,000 won. The local currency was quoted at 1,373.1 won against the greenback at 3:30 p.m., up 7 won from the previous session. (Yonhap)
Korea Herald
2 hours ago
- Korea Herald
International Healthcare Week 2025 - Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and drives economic growth throughout the healthcare sector. With over 900 leading local, regional, and international exhibitors showcasing more than 15,000 products and services, and an expected attendance of 21,000 professionals from over 50 countries, IHW 2025 offers unmatched opportunities for networking, knowledge exchange, and business development. One Venue, Five Healthcare Trade Sh ows, One Unmissable Event IHW 2025 integrates five flagship international trade exhibitions under one roof, covering the entire healthcare value chain and enhancing opportunities to learn, collaborate, invest, and showcase innovations across healthcare sectors, noted Rungphech (Rose) Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Each exhibition is complemented by dedicated conferences tailored to the specific needs and developments of their respective industries: "Participants at IHW 2025 will have the unique advantage of exploring multiple healthcare sectors and attending 125 conference sessions tailored to diverse healthcare domains - all within a single venue. This integrated format eliminates the need to travel between separate events, allowing attendees to maximise their time and resources while gaining a comprehensive understanding of the latest market trends, innovative technologies, and cutting-edge solutions," said Rungphech. Malaysia – Leading the Way in Healthcare "Malaysia's robust healthcare market expansion, flourishing medical tourism sector, strategic regional location, supportive government initiatives, and ongoing advancements in healthcare infrastructure collectively establish the country as an ideal host for IHW 2025. This event will further cement Malaysia's status as a premier healthcare hub in ASEAN and serve as a gateway for global healthcare collaboration," highlighted Rungphech. As ASEAN Chair in 2025, Malaysia plays a pivotal role in promoting regional healthcare cooperation, addressing critical challenges such as supply chain resilience, digital health adoption, and sustainable health financing through platforms like the EU-ASEAN Health Summit. Strengthening Regional Healthcare Cooperation IHW 2025 is fully aligned with ASEAN's strategic objectives to bolster healthcare systems, enhance health outcomes, and promote equitable access across member states. The event serves as a vital platform for fostering networking and partnerships essential for advancing cross-border collaboration, policy harmonization, and increased investment in healthcare infrastructure and services. This collaborative environment supports key regional initiatives including digital health integration, combating non-communicable diseases, and pandemic preparedness-priorities underscored by recent public health challenges in Southeast Asia. MATRADE: A Strong and Strategic Partner As a valued partner of International Healthcare Week 2025, the Malaysia External Trade Development Corporation (MATRADE), Malaysia's national trade promotion agency, plays a crucial role in enhancing Malaysia's global visibility and reputation in the healthcare sector. Through promotion and fostering international collaborations, MATRADE actively positions Malaysia as a regional medical hub for Southeast Asia and beyond. YB Dato' Seri Reezal Merican Naina Merican, Chairman of MATRADE, emphasized the significance of IHW 2025, stating, "International Healthcare Week serves as a powerful platform that elevates Malaysia's standing as a regional leader in healthcare and medical services. This leading event not only promotes innovation but also directly contributes to our nation's economic growth by attracting world-class exhibitors, regional and international delegates, and top healthcare experts to Malaysia—fueling trade, knowledge sharing, and industry advancement." Join Us at IHW 2025 Healthcare professionals are invited to register online at to secure their place at this free-to-attend event. Don't miss this exceptional opportunity to contribute to shaping the future of the vibrant and evolving healthcare industry in ASEAN and beyond! About Informa Markets Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Boating, Food, Fashion, and Infrastructure. As the world's leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
Korea Herald
2 hours ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
